| Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study | Lancet Respiratory Medicine | 3 days | save |  |  |  |  |
| A new once-daily long-acting β2-adrenoceptor agonist–inhaled corticosteroid combination therapy for asthma | Lancet Respiratory Medicine | 3 days | save | | | | |
| Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study | Lancet Respiratory Medicine | 3 days | save | | | | |
| Assessing the benefits of triple versus dual fixed-dose combinations for the treatment of severe asthma | Lancet Respiratory Medicine | 3 days | save | | | | |
| Integrated sports and respiratory medicine in the aftermath of COVID-19 | Lancet Respiratory Medicine | 3 days | save | | | | |
| COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? | Lancet Respiratory Medicine | 6 days | save | | | | |
| Child poverty, food insecurity, and respiratory health during the COVID-19 pandemic | Lancet Respiratory Medicine | 13 days | save | | | | |
| Identification of pathophysiological patterns for triage and respiratory support in COVID-19 | Lancet Respiratory Medicine | 16 days | save | | | | |
| Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study | Lancet Respiratory Medicine | 16 days | save | | | | |
| Small airway dysfunction: not so silent after all? | Lancet Respiratory Medicine | 16 days | save | | | | |
| Asthma in children during the COVID-19 pandemic: lessons from lockdown and future directions for management | Lancet Respiratory Medicine | 17 days | save | | | | |
| COVID-19 heralds a new era for chronic diseases in primary care | Lancet Respiratory Medicine | 17 days | save | | | | |
| Use of aerosolised medications at home for COVID-19 | Lancet Respiratory Medicine | 20 days | save | | | | |
| Health equity and distributive justice considerations in critical care resource allocation | Lancet Respiratory Medicine | 20 days | save | | | | |
| Prone positioning in non-intubated patients with COVID-19: raising the bar | Lancet Respiratory Medicine | 23 days | save | | | | |
| Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study | Lancet Respiratory Medicine | 23 days | save | | | | |
| Correction to Lancet Respir Med 2020; published online May 2. https//doi.org/10.1016/S2213-2600(20)30154-5 | Lancet Respiratory Medicine | 24 days | save | | | | |
| Delivering evidence-based critical care for mechanically ventilated patients with COVID-19 | Lancet Respiratory Medicine | 26 days | save | | | | |
| Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities | Lancet Respiratory Medicine | 26 days | save | | | | |
| Influenza immunisation in pregnancy is efficacious and safe, but questions remain | Lancet Respiratory Medicine | 26 days | save | | | | |
| Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials | Lancet Respiratory Medicine | 26 days | save | | | | |
| Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | Lancet Respiratory Medicine | 26 days | save | | | | |
| Lung function testing in the COVID-19 endemic | Lancet Respiratory Medicine | 44 days | save | | | | |
| Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Lancet Respiratory Medicine | 44 days | save | | | | |
| Testing for COVID-19 | Lancet Respiratory Medicine | 44 days | save | | | | |
| Targeting MET amplification in EGFR-mutant non-small-cell lung cancer | Lancet Respiratory Medicine | 44 days | save | | | | |
| Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans | Lancet Respiratory Medicine | 46 days | save | | | | |
| Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission | Lancet Respiratory Medicine | 46 days | save | | | | |
| Increased cardiovascular mortality in African Americans with COVID-19 | Lancet Respiratory Medicine | 46 days | save | | | | |
| Tobacco smoking and COVID-19 infection | Lancet Respiratory Medicine | 48 days | save | | | | |
| Organoids of human airways to study infectivity and cytopathy of SARS-CoV-2 | Lancet Respiratory Medicine | 52 days | save | | | | |
| Novel viruses, old data, and basic principles: how to save lives and avoid harm amid the unknown | Lancet Respiratory Medicine | 52 days | save | | | | |
| Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 | Lancet Respiratory Medicine | 53 days | save | | | | |
| Challenges in the interpretation and application of typical imaging features of COVID-19 | Lancet Respiratory Medicine | 55 days | save | | | | |
| Correction to Lancet Respir Med 2020; 8: e21 | Lancet Respiratory Medicine | 55 days | save | | | | |
| Delayed diagnosis of COVID-19 in a 34-year-old man with atypical presentation | Lancet Respiratory Medicine | 55 days | save | | | | |
| COVID-19 and the impact of social determinants of health | Lancet Respiratory Medicine | 55 days | save | | | | |
| Walking the line between benefit and harm from tracheostomy in COVID-19 | Lancet Respiratory Medicine | 58 days | save | | | | |
| Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy | Lancet Respiratory Medicine | 58 days | save | | | | |
| Tracheostomy in the COVID-19 era: global and multidisciplinary guidance | Lancet Respiratory Medicine | 58 days | save | | | | |
| Pulmonary fibrosis secondary to COVID-19: a call to arms? | Lancet Respiratory Medicine | 58 days | save | | | | |
| Management of acute kidney injury in patients with COVID-19 | Lancet Respiratory Medicine | 59 days | save | | | | |
| SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors | Lancet Respiratory Medicine | 60 days | save | | | | |
| Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities | Lancet Respiratory Medicine | 63 days | save | | | | |
| Assessment of SARS-CoV-2 replication in the context of other respiratory viruses | Lancet Respiratory Medicine | 66 days | save | | | | |
| Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures | Lancet Respiratory Medicine | 66 days | save | | | | |
| Airway management for COVID-19: a move towards universal videolaryngoscope? | Lancet Respiratory Medicine | 68 days | save | | | | |
| Immunomodulation in COVID-19 | Lancet Respiratory Medicine | 69 days | save | | | | |
| A 5-point strategy for improved connection with relatives of critically ill patients with COVID-19 | Lancet Respiratory Medicine | 69 days | save | | | | |
| South America prepares for the impact of COVID-19 | Lancet Respiratory Medicine | 74 days | save | | | | |
| | 
report | next » |
| |
